Kazia Therapeutics Limited
KZIA
$3.30
-$0.2395-6.77%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 18,900.00% | 18,866.67% | -- | -- | -- |
| Total Revenue | 272,400.00% | 271,833.33% | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 272,400.00% | 271,833.33% | -- | -- | -- |
| SG&A Expenses | 106.33% | 101.24% | 5.56% | 2.00% | 45.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 107.05% | 101.94% | -35.45% | -37.62% | -17.71% |
| Operating Income | -83.78% | -79.24% | 35.45% | 37.62% | 17.72% |
| Income Before Tax | -154.42% | -148.13% | 35.30% | 37.48% | 44.74% |
| Income Tax Expenses | 1.33% | 3.89% | 0.90% | 4.10% | -143.01% |
| Earnings from Continuing Operations | -157.48% | -151.13% | 35.64% | 37.81% | 45.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -157.48% | -151.13% | 35.64% | 37.81% | 45.57% |
| EBIT | -83.78% | -79.24% | 35.45% | 37.62% | 17.72% |
| EBITDA | -92.09% | -87.35% | 37.99% | 40.08% | 18.67% |
| EPS Basic | -99.59% | -94.66% | 60.90% | 62.22% | 67.54% |
| Normalized Basic EPS | -33.99% | -30.68% | 61.19% | 62.50% | 51.04% |
| EPS Diluted | -99.57% | -94.64% | 60.90% | 62.22% | 67.54% |
| Normalized Diluted EPS | -33.99% | -30.68% | 61.19% | 62.50% | 51.04% |
| Average Basic Shares Outstanding | 29.01% | 29.01% | 64.62% | 64.62% | 67.70% |
| Average Diluted Shares Outstanding | 29.28% | 29.28% | 64.83% | 64.83% | 68.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |